DPP4 and bullous pemphigoid: These adverse reactions have been thoroughly reviewed about insulin and other oral agents however the literature on the cutaneous adverse effects of DPP-4 inhibitors is scarce and mainly based on case reports or small case series, with bullous pemphigoid (BP) being the only exception that has been studied in RCTs and large cohort studies.